AbbVie

News

Neurocrine slides as schizophrenia data disappoints

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors.

News

AMPLIFY results dial up Calquence's potential in CLL

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuste

News

AbbVie's new chief scientific officer Roopal Thakkar (l), who is replacing Thomas Hudson (r)

AbbVie lines up Thakkar to replace outgoing CSO Hudson

There is change at the top of AbbVie’s R&D organisation, as chief scientific officer Thomas Hudson announces his retirement after four years in the role.

News

BMS hands back rights to cancer ADC licensed from Eisai

Bristol-Myers Squibb has ended a $3.1 billion strategic collaboration with Eisai focusing on antibody-drug conjugates (ADCs) and returned rights to the lead drug in the alliance.

News

AbbVie breaks new ground for IL-23 drug Skyrizi in IBD

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) –

News

AbbVie licenses FutureGen IBD drug in $1.7bn deal

The high value attached by pharma companies to inflammation and immunology (I&I) programmes is on display once again, as AbbVie agrees a deal worth up to $1.7 billion for an inflammator

Neurocrine slides as schizophrenia data disappoints

AMPLIFY results dial up Calquence's potential in CLL

AbbVie lines up Thakkar to replace outgoing CSO Hudson

BMS hands back rights to cancer ADC licensed from Eisai

AbbVie breaks new ground for IL-23 drug Skyrizi in IBD

AbbVie licenses FutureGen IBD drug in $1.7bn deal

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks